Empagliflozin's effect on small blood vessels in cardiogenic shock
Part of Heart & circulation clinical trials.
This study looks at whether empagliflozin, a diabetes medicine, helps improve blood flow in tiny blood vessels for people in cardiogenic shock. If it helps, it could improve recovery for people with this serious heart condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are already part of the main EMPASHOCK study.
- You are 18 years or older.
- You are in the intensive care unit for cardiogenic shock (when the heart can't pump enough blood).
- You have been on medicines to support blood pressure (catecholamines) for at least 12 hours.
- You can swallow tablets.
- You are not currently on dialysis or have very poor kidney function.
- You are not allergic to empagliflozin or similar medicines.
- You do not have type 1 diabetes.
- You are not pregnant or breastfeeding, or if you could become pregnant, you agree to use effective contraception.
- You do not have certain heart conditions or situations that would exclude you (like being a heart transplant recipient or having shock from other causes).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether starting empagliflozin early in adults with cardiogenic shock helps people live longer and have fewer hospital returns, while also checking heart pumping and kidney function. It may help some ICU patients, but eligibility is strict and depends on kidney function and prior medication use.
This trial tests whether a diabetes drug called dapagliflozin can help repair damaged small blood vessels in patients with septic shock. It is for people recently diagnosed with septic shock who have signs of poor blood flow to the skin.
This trial tests whether empagliflozin, a medication for heart failure, can help people who also have end-stage kidney disease and are on dialysis. It aims to see if the drug improves heart function in this group.
This trial tests whether a medicine called empagliflozin (used for diabetes and heart failure) can help people with both heart failure (with preserved pumping ability) and end-stage kidney disease who are on dialysis. The study looks at how the drug affects heart function and overall well-being.
This trial tests whether giving empagliflozin (a diabetes medicine that may protect the heart) before or after emergency angioplasty for a first heart attack is better than a placebo. It aims to see if this medicine can improve recovery in South Asian patients.
This study tests whether a medication called empagliflozin (a diabetes drug) can improve heart function in older adults with high blood pressure and obesity who are at risk for heart failure but do not have it yet. You would take the pill daily and have heart ultrasounds to check your heart's health.
Hear when a new Cardiogenic Shock trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.